22 results
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
25 Apr 24
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024
8:03am
to infections and then monitoring the potential progression of an individual’s T-Cell functions following chronic antigen stimulation.”
About Post-Viral … several factors are believed to play a role. These factors include problems with the immune system, such as ongoing chronic inflammation, autoimmunity
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
16 Apr 24
Virax Biolabs Group Limited to Participate at ESCMID Global 2024
7:34am
and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
15 Mar 24
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
4:32pm
effective in the diagnosis and therapeutics of Long COVid as well as chronic inflammation and other post viral syndromes including myalgic encephalomyelitis
424B5
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Prospectus supplement for primary offering
5:27pm
syndromes associated with T-cell exhaustion and chronic fatigue through the provision of diagnostic tests, tests for adaptive immunity and education … and chronic fatigue. We are in the process of developing a T-Cell Test under the ViraxImmune brand and will apply for regulatory agency approval. We
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
12 Jan 24
Current report (foreign)
7:43am
of post viral syndromes associated with T-cell exhaustion and chronic fatigue through the provision of diagnostic tests, tests for adaptive immunity
6-K
EX-99.2
oun18y
12 Jan 24
Current report (foreign)
7:43am
6-K
EX-99.1
yt54ek59hd2jdxm5eox
21 Dec 23
Current report (foreign)
7:34am
424B3
x50rceifu vh2a
20 Dec 23
Prospectus supplement
4:03pm
6-K
EX-99.1
ox60u1skx81dhejwn
18 Dec 23
Virax Biolabs’ CEO James Foster Issues Letter to Shareholders
7:37am
F-3
blkp4
5 Dec 23
Shelf registration (foreign)
4:06pm
20-F
9tt0 p0ud4pdmhe
12 Aug 22
Annual report (foreign)
4:20pm
424B4
c6ocb
21 Jul 22
Prospectus supplement with pricing info
10:01am
F-1/A
gnjzens8xlw x885z
24 Jun 22
Registration statement (foreign) (amended)
9:47pm
F-1/A
lj72gj9x7ozfr4 cr
24 Jun 22
Registration statement (foreign) (amended)
8:21am
F-1/A
fvv9fe gq6
21 Jun 22
Registration statement (foreign) (amended)
6:26am
F-1/A
94caf
6 Jun 22
Registration statement (foreign) (amended)
6:13pm
F-1/A
m9k1rqm
11 May 22
Registration statement (foreign) (amended)
3:11pm
F-1/A
4btae95zuq 3f4
22 Apr 22
Registration statement (foreign) (amended)
6:09pm
F-1
6tjdlpl
18 Mar 22
Registration statement (foreign)
3:50pm